Angelique Acquatella, Keith Marzilli Ericson & Amanda Starc
Abstract: We examine cost-plus lagged-price reimbursement contracts, focusing on Medicare Part B’s payment for physician-administered drugs. Our theoretical model shows that lagged-price reimbursement can raise launch prices but lower prices in later periods. While previous research showed Part B increased launch prices, we estimate its effect on later prices (net of rebates). Drugs more exposed to Medicare have lower price growth. A drug with above median Part B exposure has a 10% lower price after 3 years than a below median exposure drug that launched at the same price, with a larger effect for newly approved molecules.
Keith Marzilli Ericson 